Vericel Corporation stock is up 4.41% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 70% of the previous 9 December’s closed higher than November. 0% of analysts rate it a buy.
Vericel Corporation engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee. Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal. NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-th thickness.